MANDIPROPAMID


Synonyms	Mandipropamid
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	KWLVWJPJKJMCSH-UHFFFAOYSA-N
Smiles	COc1cc(CCNC(=O)C(OCC#C)c2ccc(Cl)cc2)ccc1OCC#C
InChI	InChI=1S/C23H22ClNO4/c1-4-14-28-20-11-6-17(16-21(20)27-3)12-13-25-23(26)22(29-15-5-2)18-7-9-19(24)10-8-18/h1-2,6-11,16,22H,12-15H2,3H3,(H,25,26)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H22ClNO4
Molecular Weight	411.88
AlogP	5.75
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	10.0
Polar Surface Area	56.79
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	29.0

Assay Description	Organism	Bioactivity
Up-regulation of CesA2 gene expression in Pythium aphanidermatum at 100 uM after 8 hr by qRT-PCR method relative to untreated control	Pythium aphanidermatum	2.0
Up-regulation of CesA1 gene expression in Pythium aphanidermatum at 100 uM after 8 hr by qRT-PCR method relative to untreated control	Pythium aphanidermatum	1.6
Inhibition of germ tube elongation of Pythium aphanidermatum synchronised cytospores at 0.5 to 121 uM after 4 hr	Pythium aphanidermatum	None
Antifungal activity against Pythium aphanidermatum assessed as inhibition of mycelial growth at 100 uM after 3 days	Pythium aphanidermatum	34.0 %
Antifungal activity against Pythium aphanidermatum assessed as inhibition of mycelial growth at 10 uM after 3 days	Pythium aphanidermatum	None

Cross References

Resources	Reference
ChEMBL	CHEMBL271907
PubChem	11292824
SureChEMBL	SCHEMBL22338

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).